Pharming Group Nv ( (PHAR) ) has released its Q1 earnings. Here is a breakdown of the information Pharming Group Nv presented to its investors.
Pharming Group N.V. is a global biopharmaceutical company focused on developing and commercializing innovative medicines for rare diseases, with a presence in over 30 markets worldwide.
In the first quarter of 2025, Pharming Group reported a significant 42% increase in total revenues, reaching $79.1 million, driven by strong performance from its flagship product RUCONEST® and the growing uptake of Joenja® (leniolisib). The company also completed the acquisition of Abliva AB, enhancing its growth trajectory with the addition of the KL1333 program for mitochondrial diseases.
Key financial highlights include a 49% revenue increase for RUCONEST® and a 9% increase for Joenja®, with the U.S. market being the primary contributor. The company reported an operating profit of $0.8 million, excluding non-recurring acquisition expenses, marking a significant improvement from the previous year’s loss. Pharming also raised its full-year revenue guidance to $325-$340 million, reflecting confidence in its growth strategy.
Strategically, Pharming is advancing its pipeline with ongoing clinical trials for leniolisib in primary immunodeficiencies and the KL1333 program. The company is also preparing regulatory filings for leniolisib in Japan and the U.S. for pediatric use, aiming to expand its market presence and address unmet medical needs.
Looking ahead, Pharming Group remains focused on driving sustainable growth through strategic capital allocation, expanding its product portfolio, and pursuing additional regulatory approvals. The company anticipates continued revenue growth and operational progress in 2025, supported by its robust pipeline and market expansion efforts.